Marketing Authorization Holders

Information for Marketing Authorization Holders

For Marketing Authorization Holders

According to the falsified medicines directive, all manufacturers must implement the two safety features 2D data matrix and tamper evidence for all human prescription medicines unless the products are listed on the “white list” (Annex I of the Delegated Regulation (EU) 2016/161).

NOMVEC is developing and implementing the Norwegian database on behalf of the pharmaceutical industry in Norway. The deadline for implementation is 9th February 2019, and the preparations to reach the deadline is on its way. The Norwegian database is nearly complete already.